| dc.contributor.author |
Papakyriakou, A |
en |
| dc.contributor.author |
Katsarou, ME |
en |
| dc.contributor.author |
Belimezi, M |
en |
| dc.contributor.author |
Karpusas, M |
en |
| dc.contributor.author |
Vourloumis, D |
en |
| dc.date.accessioned |
2014-06-06T06:50:12Z |
|
| dc.date.available |
2014-06-06T06:50:12Z |
|
| dc.date.issued |
2010 |
en |
| dc.identifier.issn |
18607179 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1002/cmdc.200900373 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/4995 |
|
| dc.subject |
Angiogenesis |
en |
| dc.subject |
Drug design |
en |
| dc.subject |
Inhibitors |
en |
| dc.subject |
Medicinal chemistry |
en |
| dc.subject |
Molecular dynamics |
en |
| dc.subject |
VEGFR-2 |
en |
| dc.subject.other |
2 (2 hydroxy 5 nitrobenzylamino) n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 (3,3 diphenylallylamino) n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 (3,5 dibromo 4 hydroxybenzyl)amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 (4 hydroxybenzyl)amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 (benzo[b]thiophen 3 ylmethylamino) n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 (perfluorobenzyl)amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 [(3 pyridyl)methyl]amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 [(4 pyridyl)methyl]amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 [(furan 2 yl)methyl]amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
2 [(thiazole 2 yl)methyl]amino n [3 (trifluoromethyl)phenyl]benzamide |
en |
| dc.subject.other |
3 (2 hydroxy 5 nitrobenzylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (2,5 dihydroxybenzylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (3,3 diphenylallylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (4 hydroxybenzylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (benzo[b]thiophen 3 ylmethylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (furan 2 ylmethylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (perfluorobenzylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (pyridin 3 ylmethylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (pyridin 4 ylmethylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
3 (thiazol 2 ylmethylamino) n [3 (trifluoromethyl)phenyl]thiophene 2 carboxamide |
en |
| dc.subject.other |
unclassified drug |
en |
| dc.subject.other |
vasculotropin inhibitor |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
controlled study |
en |
| dc.subject.other |
cytotoxicity |
en |
| dc.subject.other |
drug inhibition |
en |
| dc.subject.other |
drug screening |
en |
| dc.subject.other |
drug synthesis |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
human cell |
en |
| dc.subject.other |
molecular dynamics |
en |
| dc.subject.other |
priority journal |
en |
| dc.subject.other |
Anthranilic Acids |
en |
| dc.subject.other |
Cell Line |
en |
| dc.subject.other |
Databases, Protein |
en |
| dc.subject.other |
Drug Discovery |
en |
| dc.subject.other |
Hela Cells |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Molecular Dynamics Simulation |
en |
| dc.subject.other |
Protein Binding |
en |
| dc.subject.other |
Protein Kinase Inhibitors |
en |
| dc.subject.other |
Vascular Endothelial Growth Factor Receptor-2 |
en |
| dc.title |
Discovery of potent vascular endothelial growth factor receptor-2 inhibitors |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1002/cmdc.200900373 |
en |
| heal.publicationDate |
2010 |
en |
| heal.abstract |
Substantial evidence over the last decades has implicated uncontrolled angiogenesis with various pathological states, including cancer. Vascular endothelial growth factor (VEGF) plays a critical role in its regulation. Because the tyrosine kinase VEGF receptor-2 (VEGFR-2) is the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF, it has become one of the most profound anti-angiogenesis targets. Inspired by the anthranilamide class of VEGFR-2 inhibitors, we performed a computational analysis of some potent representative members, using docking and molecular dynamics calculations. Based on the observations drawn from introducing the effect of the receptor's flexibility in implicit aqueous environment, we designed, synthesized, and characterized several new analogues of related scaffolds with modifications in their steric and electronic characteristics. In vitro evaluation of these compounds revealed several novel VEGFR-2 inhibitors that are less cytotoxic and more potent than the parent compounds. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA. |
en |
| heal.journalName |
ChemMedChem |
en |
| dc.identifier.issue |
1 |
en |
| dc.identifier.volume |
5 |
en |
| dc.identifier.doi |
10.1002/cmdc.200900373 |
en |
| dc.identifier.spage |
118 |
en |
| dc.identifier.epage |
129 |
en |